-
Lilly Weight Loss Medicine Approved by US FDA, Developed by Domestic Pharmaceutical Companies Press "Acceleration Key"
On November 8th local time, American pharmaceutical giant Lilly announced that its GLP-1R/GIPR dual target agonist, Tilposide Injection Zepbound, has been approved by the US Food and Drug Administrat ... -
Top 20 US Stock Deals: Pfizer Encounters Double Killing Lawsuit between Diet Drugs and COVID-19 Vaccine
[The top 20 US stock turnover: Pfizer suffered a double battle between weight-loss drugs and COVID-19 vaccine litigation] The 12th Pfizer Pharmaceutical closed down 5.12%, the largest one-day decline ... -
Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
Johnson&Johnson CEO Joaquin Duato stated at the company's Investor Day event on December 5th that the company currently has no plans to produce weight loss pills due to the intense competition in the ... -
Novo Nordisk tests the efficacy of its weight loss medication on alcoholic liver disease
On May 15th, it was reported that Novo Nordisk is conducting trials on its weight loss drugs to explore whether they can reduce alcohol intake and treat alcoholic liver disease. The company is seekin ... -
Lilly: We have applied to the FDA for the weight loss drug Zepbound to treat sleep apnea, and it is expected to be approved as early as the end of the year
According to AI News, according to CNBC, Lilly has applied to the United States for approval of its weight loss drug Zepbound for the treatment of the most common sleep related respiratory disorders, ... -
Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals regarding the patent dispute over the weight loss drugs Ozempic and Wegovy. Novo Nordisk and Mylan Pharmaceuticals, a subsidiary of Vi ...